Australia - English - Department of Health (Therapeutic Goods Administration)

ausphex pty ltd - natural fish oil -

Australia - English - Department of Health (Therapeutic Goods Administration)

ausphex pty ltd - natural fish oil -

Australia - English - Department of Health (Therapeutic Goods Administration)

ausphex pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

ausphex pty ltd - ubidecarenone -

Australia - English - Department of Health (Therapeutic Goods Administration)

ausphex pty ltd - natural fish oil -

United States - English - NLM (National Library of Medicine)

eisai inc. - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg - aciphex delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd).  for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of aciphex may be considered. aciphex delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance).  controlled studies do not extend beyond 12 months. aciphex delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks.  aciphex delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers.  most patients heal within four weeks. aciphex delayed-release tablets, in combination with amoxicillin and clarithromycin as

United States - English - NLM (National Library of Medicine)

woodward pharma services llc - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - aciphex delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of aciphex may be considered. aciphex delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. aciphex delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks. aciphex delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. most patients heal within four weeks. aciphex delayed-release tablets, in combination with amoxicillin and clarithromycin as a

United States - English - NLM (National Library of Medicine)

aphex biocleanse systems, inc - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - active ingredients: benzalkonium chloride 0.11% - 0 .13% (as sanitizing agent)

United States - English - NLM (National Library of Medicine)

aphex biocleanse systems, inc - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - uses: for hand sanitizing. helps prevent the risk and spread of infection as well as communicable diseases by killing germs that reside on the surface of the skin. active ingredients: benzalkonium chloride 0.11% - 0 .13% (as sanitizing agent)

United States - English - NLM (National Library of Medicine)

aphex biocleanse systems, inc - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - uses: for hand sanitizing. helps prevent the risk and spread of infection as well as communicable diseases by killing germs that reside on the surface of the skin. active ingredients: benzalkonium chloride 0.11% - 0 .13% (as sanitizing agent)